Human epidermal growth factor receptor 2 (HER2) overexpression in primary breast cancer is associated with a poor prognosis in 15%–20% of cases, and almost 50% of HER2‐positive breast cancers do not express hormone receptors (HRs) [2]. This evidence concerns the gene NR4A1 and breast carcinoma.